Cambridge Epigenetix Licenses Fundamental DNA Methylation IP from Boston Children’s Hospital

Product News   Apr 28, 2017 | Original story from Cambridge Epigenetix

 
Cambridge Epigenetix Licenses Fundamental DNA Methylation IP from Boston Children’s Hospital

Anjana Rao. Credit: Cambridge Epigenetix

 
 
FURTHER INFORMATION
 
 
 

Related Product News

QIAGEN Receives FDA Approval to Expand Use of EGFR Test in Lung Cancer

Product News

Extended labeling claim adds detection of three additional gene mutations to provide the most comprehensive mutation panel for GILOTRIF®

READ MORE

Thermo Fisher Scientific Expands Oncomine Portfolio

Product News

New pan-cancer cell-free total nucleic acid (cfTNA) assay and FFPE-based tumor mutation load analysis assay, coupled with new Ion AmpliSeq HD technology, extend industry-leading Oncomine menu and enable panel design customization.

READ MORE

Thermo Fisher Scientific Introduces Ion GeneStudio S5 Series of Next Generation Sequencers

Product News

Thermo Fisher Scientific today announced the Ion GeneStudio S5 Series, a new line of bench top next-generation sequencing (NGS) instruments that enable low cost per sample for small and large projects across multiple research applications.

READ MORE

Like what you just read? You can find similar content on the communities below.

Cancer Research Diagnostics Proteomics & Metabolomics

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE